Adage Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$89M Buy
1,466,671
+1,033,502
+239% +$60.2M 0.14% 151
2025
Q4
$23.4M Sell
433,169
-146,892
-25% -$7.07M 0.04% 435
2025
Q3
$26.2M Buy
580,061
+384,097
+196% +$17.9M 0.04% 394
2025
Q2
$9.07M Sell
195,964
-1,756,304
-90% -$86.2M 0.02% 634
2025
Q1
$119M Sell
1,952,268
-5,816,959
-75% -$339M 0.22% 93
2024
Q4
$439M Buy
7,769,227
+3,275,061
+73% +$183M 0.77% 17
2024
Q3
$233M Buy
4,494,166
+3,622,532
+416% +$170M 0.41% 37
2024
Q2
$36.2M Buy
+871,634
New +$39M 0.07% 286
2023
Q4
Sell
-160,188
Closed -$9.3M 862
2023
Q3
$9.3M Buy
+160,188
New +$9.82M 0.02% 574
2023
Q2
Sell
-412,918
Closed -$28.6M 874
2023
Q1
$28.6M Sell
412,918
-440,848
-52% -$31.1M 0.06% 327
2022
Q4
$61.4M Sell
853,766
-1,372,229
-62% -$103M 0.15% 169
2022
Q3
$158M Buy
2,225,995
+1,228,935
+123% +$89.1M 0.39% 44
2022
Q2
$76.8M Buy
997,060
+430,260
+76% +$32.8M 0.18% 122
2022
Q1
$41.4M Buy
566,800
+62,900
+12% +$4.22M 0.08% 262
2021
Q4
$31.4M Sell
503,900
-309,539
-38% -$18.2M 0.06% 336
2021
Q3
$48.1M Sell
813,439
-559,300
-41% -$36.8M 0.09% 221
2021
Q2
$91.7M Sell
1,372,739
-66,400
-5% -$4.33M 0.18% 118
2021
Q1
$90.9M Sell
1,439,139
-447,100
-24% -$27.8M 0.19% 128
2020
Q4
$117M Sell
1,886,239
-329,565
-15% -$20.3M 0.26% 85
2020
Q3
$134M Buy
+2,215,804
New +$133M 0.33% 61
2020
Q2
Sell
-2,197,289
Closed -$122M 736
2020
Q1
$122M Sell
2,197,289
-10,250
-0.5% -$626K 0.37% 61
2019
Q4
$142M Buy
+2,207,539
New +$126M 0.35% 65
2019
Q2
Sell
-851,920
Closed -$40.6M 714
2019
Q1
$40.6M Sell
851,920
-933,705
-52% -$46.5M 0.1% 239
2018
Q4
$92.8M Buy
1,785,625
+24,735
+1% +$1.33M 0.26% 110
2018
Q3
$109M Buy
1,760,890
+124,180
+8% +$7.37M 0.24% 109
2018
Q2
$90.6M Sell
1,636,710
-1,097,640
-40% -$59.3M 0.21% 124
2018
Q1
$173M Buy
2,734,350
+407,846
+18% +$26.2M 0.4% 60
2017
Q4
$143M Buy
2,326,504
+466,920
+25% +$29.2M 0.32% 80
2017
Q3
$119M Sell
1,859,584
-174,400
-9% -$10.2M 0.29% 85
2017
Q2
$113M Buy
2,033,984
+615,900
+43% +$33.5M 0.28% 95
2017
Q1
$77.1M Sell
1,418,084
-1,205,969
-46% -$66.1M 0.19% 151
2016
Q4
$153M Buy
2,624,053
+202,200
+8% +$11.1M 0.42% 54
2016
Q3
$131M Sell
2,421,853
-2,973,245
-55% -$191M 0.36% 72
2016
Q2
$397M Sell
5,395,098
-313,098
-5% -$22.1M 1.08% 7
2016
Q1
$365M Buy
5,708,196
+98,600
+2% +$6.22M 0.99% 7
2015
Q4
$386M Buy
5,609,596
+1,143,000
+26% +$75.5M 1.01% 6
2015
Q3
$264M Sell
4,466,596
-606,100
-12% -$38.4M 0.73% 22
2015
Q2
$338M Sell
5,072,696
-1,980,495
-28% -$131M 0.84% 13
2015
Q1
$455M Buy
7,053,191
+2,275,000
+48% +$142M 1.11% 5
2014
Q4
$282M Buy
4,778,191
+162,433
+4% +$9.16M 0.69% 16
2014
Q3
$236M Sell
4,615,758
-336,800
-7% -$16.8M 0.58% 30
2014
Q2
$240M Sell
4,952,558
-2,240,100
-31% -$110M 0.62% 31
2014
Q1
$374M Sell
7,192,658
-1,567,200
-18% -$83.4M 1.02% 9
2013
Q4
$466M Buy
8,759,858
+905,000
+12% +$46.1M 1.23% 7
2013
Q3
$364M Sell
7,854,858
-2,180,000
-22% -$95.7M 1.05% 8
2013
Q2
$448M Buy
+10,034,858
New +$436M 1.38% 3

Other funds holding BMY

Adage Capital Partners's BMY Position: Q1 2026 in Review

Adage Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 239% in Q1 2026, buying an estimated $60.2M and bringing the position to 1,466,671 shares worth $89M. The position accounts for 0.14% of the portfolio, ranked #151.

Adage Capital Partners first reported a position in BMY in Q2 2013 and has held it in 46 quarters since. The position peaked at $466M in Q4 2013. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Adage Capital Partners held 1,466,671 shares of Bristol-Myers Squibb worth $89M as of Q1 2026.
  • Adage Capital Partners bought 1,033,502 Bristol-Myers Squibb shares in Q1 2026, an estimated $60.2M.
  • Bristol-Myers Squibb made up 0.14% of Adage Capital Partners's portfolio in Q1 2026, its #151 holding.
  • Adage Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 46 quarters since.
  • Adage Capital Partners's Bristol-Myers Squibb position peaked at $466M in Q4 2013.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.